Orit Picard
Sheba Medical Center(IL)
Publications by Year
Research Areas
Inflammatory Bowel Disease, Microscopic Colitis, Immunodeficiency and Autoimmune Disorders, Gut microbiota and health, Biosimilars and Bioanalytical Methods
Most-Cited Works
- → Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases(2015)361 cited
- → Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease(2012)303 cited
- → The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab(2013)299 cited
- → The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful(2010)204 cited
- → Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima(2015)174 cited
- → Association of Vedolizumab Level, Anti-Drug Antibodies, and α4β7 Occupancy With Response in Patients With Inflammatory Bowel Diseases(2017)122 cited
- → Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab(2016)115 cited
- → Adalimumab Level in Breast Milk of a Nursing Mother(2009)112 cited
- → Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease(2011)110 cited
- → Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies(2011)85 cited